Ocrevus effective in halting MS disease activity for Black, Hispanic patients at 1 year

Ocrevus infusions were effective in halting disease activity in Black and Hispanic individuals with relapsing forms of multiple sclerosis after 1 year, according to a study presented at ECTRIMS 2023.
“Black and Hispanic patients are underrepresented in multiple sclerosis trials but may have higher MS incidence, faster disease progression and/or an increased risk of progression to disability vs. white patients,” Mitzi Joi Williams, MD, of the Joi Life Wellness MS Center in Atlanta, and colleagues wrote.
Williams and fellow researchers conducted the CHIMES trial, intended to evaluate

Ocrevus infusions were effective in halting disease activity in Black and Hispanic individuals with relapsing forms of multiple sclerosis after 1 year, according to a study presented at ECTRIMS 2023.
“Black and Hispanic patients are underrepresented in multiple sclerosis trials but may have higher MS incidence, faster disease progression and/or an increased risk of progression to disability vs. white patients,” Mitzi Joi Williams, MD, of the Joi Life Wellness MS Center in Atlanta, and colleagues wrote.
Williams and fellow researchers conducted the CHIMES trial, intended to evaluate